Compare Hims and Hers Health Inc (HIMS) vs Paychex, Inc. (PAYX) Price & Performance

Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.

The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.

Paychex (PAYX) trades at $101.55, up 0.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 27.35% net income margin and a 47.06% ROE, but valuation metrics like a P/E of 20.15 and P/S of 5.52 suggest a premium. Recent news highlights concerns over dividend sustainability and a 14% stock decline, even as the company reported double-digit earnings growth driven by PEO and insurance segments.

The outlook is mixed: solid fundamentals and a consensus price target of $111.00 imply upside, but bearish technicals and investor skepticism about growth levers like AI pose risks. Key opportunities include consistent dividend payments and market leadership, while risks involve labor market sensitivity and high debt levels following a significant increase in total liabilities.